Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Hims & Hers Health has sold off ~40% GLP-1 turbulence, but the core growth story remains intact. Read why HIMS stock is a ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

Discover the top 11 websites to buy GLP-1 weight loss medications online. Our expert-reviewed guide helps you find safe, ...

HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

A newly released survey from over 3,000 Americans indicates that people 45 years old and over are becoming increasingly lonely.

Novo Nordisk enters the final stretch of 2025 looking almost unrecognizable from the market darling it was just months ago.

I don’t feel like I’m dragging anymore.” So far, he has experienced no side effects and plans to continue microdosing as long ...

For a 45-year-old who pays out of pocket for Wegovy, the cost comes to $3,900 a year - even with the discounts. For a Medicare beneficiary, that cost will be $600 a year in copays. But some research ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.